Compare · DXCM vs OFIX
DXCM vs OFIX
Side-by-side comparison of DexCom Inc. (DXCM) and Orthofix Medical Inc. (OFIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and OFIX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 67.6x OFIX ($415.9M).
- Over the past year, DXCM is down 10.8% and OFIX is down 7.5% - OFIX leads by 3.3 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 5 for OFIX).
- DXCM has more recent analyst coverage (25 ratings vs 10 for OFIX).
- Company
- DexCom Inc.
- Orthofix Medical Inc.
- Price
- $76.55+5.08%
- $10.23-0.39%
- Market cap
- $28.11B
- $415.9M
- 1M return
- +25.34%
- -15.28%
- 1Y return
- -10.82%
- -7.50%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 1992
- News (4w)
- 26
- 5
- Recent ratings
- 25
- 10
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest OFIX
- SEC Form 4 filed by Large owner Juniper Investment Company, Llc
- New insider Juniper Investment Company, Llc claimed ownership of 4,200,543 shares (SEC Form 3)
- SEC Form SD filed by Orthofix Medical Inc.
- Orthofix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Orthofix to Participate in Upcoming Investor Conferences
- Director Henneman John B Iii bought $61,295 worth of shares (5,000 units at $12.26), increasing direct ownership by 6% to 90,809 units (SEC Form 4)
- Large owner Engine Capital Management, Lp bought $2,232,927 worth of shares (184,896 units at $12.08) (SEC Form 4)
- Orthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting
- SEC Form 10-Q filed by Orthofix Medical Inc.
- Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits